We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Myhealthchecked Plc | MHC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 1.85 | 12.13% | 17.10 | 12:27:07 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 15.25 | 15.25 | 17.50 | 15.25 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 19/1/2025 15:29 by tia01 KeithIf MHC plans to be part of a revolutionary change to the NHS plans for patients along with Boots who clearly have the facilities in place then this is a game changer. A situation where markets will immediately cotton on to the impact it will have on revenue. All my personal opinion but Boots are the key and that explains the deal with pharmacy 2U and MHCs focus of the digital data. Local GPs in a surgery are outdated dull and boring and most of all not cost effective. AI is the way forward and Poc Doc deals demonstrate the vision MHC has. I recently bought into a company TRLS who did a 700% in a day this week on news of a deal with Johnson & Johnson. It’s a bowl inflammation company that specialises in colitis etc and its focus is based on AI and digital data etc. so clearly Johnson & Johnson understands the future. What people don’t understand is Penny has close ties to this company through the previous Director and if there’s a way to collaborate Penny will be onto it like a rash. Also I see more announcements on Both Donald and Stephen buying in weeks or months ahead as news flows. Should we follow the constant buying patterns of large shareholders. Do they know something or Just visionary people like Elon Musk was! Who know |
Posted at 19/1/2025 13:59 by tia01 So what can we expect in update!.New products bedding in well. HIV tests selling well. Poc Doc rolling out strategy. Pharmacy 2U sale/plans update News on Boots deal! Strong revenue from Covid to continue self funded growth plan. New products plans. Strong balance sheet. Plans to help cut GP lists using Boots and MHC. Read link attached News that could be significant NHS plans with Boots and MHC however this may need to be finalised. Possible Dividends but doubtful. Any significant rise in share price could lead to an opportunity to raise funds for growth by acquisition route. Overall I expect a positive update and truly expect more large shareholders to take advantage of low Market Cap and well undervalued shares based on fundamentals and strategy. |
Posted at 14/1/2025 18:35 by tia01 Tia is back lol.Been busy today getting hernia looked at. Anyway what a day. Phlebotomy falling into place but this is only a warm up to the big news with GPs Boots and MHC helping to reduce GP waiting lists. positive update this month suggesting a huge rise in wellness tests. Don’t forget Poc Doc which is due to commence shortly and also pharmacy 2U!. It’s clear why MHC is aligned to pharmacy’s. The potential to have access to millions on the NHS is game changing and an10 bagger could follow. Well let’s not get career away but 100% one of the exiting share for 2025 and will make labour look like they have reduced waiting lists significantly. Amazing given only 52m shares in circulation!. Who is Donald or Stephen! |
Posted at 01/1/2025 20:43 by tia01 I have carefully looked at MHC and asked questions does it have the ability to be a market disrupter in the sector!My conclusion is absolutely yes. If MHC can introduce phlebotomy testing in half of the Boots stores and can manage to make use of it’s digital data and recent approvals in 2024 it definitely has the ability to shake up testing in the NHS. MHC has demonstrated its digital data and ability to meet strict compliance regulations regarding testing can seriously help reduce waiting lists at local GPs. After all most patients get prescriptions and use Boots chemist to receive medication. Surely the next step is to offer in house phlebotomy testing instead the lengthy process currently in place at local GPs. We also have a deal to distribute the Poc Doc tests starting this month hopefully so we can expect news imminently. I would strongly say MHC can suddenly ramp up revenue if a deal with Boots is announced. I’m sure Penny is currently working on it and Boots will equally be keen to change the way GPs treat patients. Definitely one to watch in the next few months. |
Posted at 18/12/2024 13:07 by tia01 ControlMany companies that employ large numbers of people are suffering since the new government took over with minimum wage and employees NI rise. This won’t be a big issue for MHC because we don’t have a large number of staff and minimum wage wouldn’t be. Concern. What’s key is 100% the news regarding VAT and news on phlebotomy testing. We need clarity on revenue streams as we move away from Covid dependency revenue. I totally believe news is on the way but unfortunately I suspect in January at the earliest. Boots clearly believe in MHC and MHC in Boots. Would love a positive update on pharmacy2U deal and Poc doc launch due in January. More B2B deals also. Is this worth more than current value!. I believe it is 100% based on fundamentals. 1, cash position 2, No dilution 3, Boots deal and products 4, Digital data investment 5, regulatory approvals 6, Poc Doc deal 7, pharmacy 2U deal. 8, cost control 9 potential to add more tests like HIV test. Time for Penny to announce deal to allow Directors to buy |
Posted at 12/12/2024 12:20 by tia01 I personally can assure you Penny has positive plans. It’s all in the last statement from both Penny and Chairman. I do understand the comments but this is no dead duck. The future of health is in self testing. NHS is definitely in crisis. MHC could easily rocket, fall or do nothing but fact they have guided the company through 4 years since pandemic without raising or diluting is testimony to a prudent management team. Would I like to see more deals!for sure 100% but I’m equally sure one is in the pipeline between Boots and MHC regarding phlebotomy testing as in the Chairman’s statement. Is this a game changer. Absolutely because GPs are overwhelmed and this government wants to cut appointments which cost NHS £50 each. Digital data and self testing go hand in hand so hopefully 2025 will be MHCs year. An update due in January and expect news on this at some point. Inevitably as they move away from Covid testing it will be volatile however deals like the Poc Doc one and HIV tests are proving that MHC can see the direction for growth. Not to forget new online pharmacy deal. We also have a possible 1.6 VAT return coming so maybe MHC are waiting for 2025 to start motoring.More added stores do in store sales should rise over Christmas for new products!. Let’s wish the team well and follow Donald Hamilton as he keeps adding on weakness. |
Posted at 27/10/2024 08:13 by tia01 DualWe know MHC has big plans and clearly in the middle of a deal that is game changing. It will clearly involve Boots and possibly government changes to pharmacy first products available to be used in stores with Boots specialists. The Poc Doc deal is significant also as it will also be sold over the counter or off the shelf. It’s all suggesting that one of the biggest killers in heart disease is a major focus so I personally see heart tests being added to the pharmacy first list. I could be wrong but the government know Boots with MHC tests and digital data can solve the GP appointment problems. Save costs and more efficient and save lives. MHC are focusing on LFT tests IMO which is why they ain’t restocked VITAMIN D tests as no margins in them. I also see a surprise and do wonder if Newfoundland may try a cheap takeover of MHC. They already supply the LFT tests and HIV tests to Boots via MHC!. They are also in many major shops but can’t get in Boots without MHC who have the required approval as you pointed out. Boots is extremely strict which is why it hasn’t stocked the prostrate tests because of the trauma it could cause after a positive test result etc. I think this may change as it’s a big issue. Chris Hoy a true ambassador and legend highlighting the need for more testing is testament to why Boots and MHC need to combine to offer a testing service to the public for NHS patients. Also note many black Caribbean suffer prostrate issues so Boots and MHC could use marketing to target the ethnic communities by highlighting this!. Anyway don’t expect and deal until the new year because of the parties involved and complexity involved. I do anticipate a market campaign to start in November to coincide with the run up to Christmas and the deal that will be announced in the new year hopefully. The focus on Covid revenue has clearly shifted towards testing and the question is can MHC get the revenue breaking deal done without a share dilution required!. I think the answer is 100 YES but equally a VAT refund will ensure the answer is yes. Also note Directors can’t buy until the deal is announced. Once again will Newfoundland be ambitious and smart enough to launch a strike for MHC knowing the potential benefits to both parties. Would MHC make a play for Newfoundland!!!! |
Posted at 27/8/2024 11:32 by muck166 Tia - I don't want to get in a spat with you about valuations, especially on the MHC board. And I am not saying MHC is a bad company - it isn't.Yes, ABDX supplies Boots with some own label tests. In fact, they are exactly the same Chinese tests that MHC also sell through Boots, just in different packaging. And yes, ABDX makes and sells pregnancy tests, as well as other tests. But even a cursory look at its accounts will show you that revenue it makes from total product sales is less than 10% of its total revenue. The bulk of its revenue comes from CDMO/CRO activities on a fee for service model, ie it helps third party lateral flow developers move an idea to a commercial, approved LFT product that can be manufactured at scale and robustly. That is its main business, and its NOT the same as MHC. I don't know why MHC has an MCAP of less than ABDX, but if I were to guess I would say it's because MHC remains heavily reliant on COVID revenue (which is falling) and seems to be stagnating rather than growing, whereas ABDX has growing revenue from a multitude of different customers and streams, as well as some huge potential in its pipe. There are very good reasons why 3 institutional investors took almost all of the recent raise at less than a 10% discount - I assume it's because they see real growth potential in ABDX. Sadly, MHC isn't showing investors anything at the moment. |
Posted at 21/8/2024 18:16 by tia01 MuckI don’t see Albington has being completely different!. Most revenue derived from a pregnancy test where MHC started life. Albington providing tests to Boots in Boots brand that MHC does in own brand. Mhc in a better state financially and remember revenue is revenue and profit is profit. However the companies are extremely similar and I’m sure mHC/concepta sold Albington it current testing premises!. I feel the financial position of MHC is 100x healthier and any one knows revenue isn’t profit |
Posted at 30/6/2024 08:52 by tia01 I took this morning to read the Chairman’s Statement and it’s clear a slowdown is expected in Covid tests in the first half of 2024.Is it all bad news! I personally see a slowdown that will see sales of Covid for first six months of 2024 to come in at around 3m based on 1 test being sold in each of the 1900 stores nationwide and also online sales during the period. You may think ouch but as stated in Chairman’s statement a decline is expected. The good thing is it’s evident the other tests provided by MHC will make up for lost revenue from the Covid tests as sales increase. I don’t expect a huge amount of revenue from new tests but it’s reasonable to expect between half a million and three quarters in the first half. So I would anticipate a similar overall figure to the first half in 2023 with combined sales and wellness tests. The key will be any update that may lead to an anticipated huge uptick in wellness test sales in Boots. We are expanding to another 200plus stores with wellness tests however this will come at a cost to MHC for the initial costs of shelving and stock etc. It will however add to the long term growth of revenue. It’s also self funded. I do expect strong cost control to reserve cash and also believe any collaboration with Boots pharmacy first and phlebotomy testing privately within Boots instore MOT services available could provide a catalyst needed. I don’t think a buy back will be announced although it would be a great idea. I believe the company will prioritise using cash for growing the business instead. I believe MHC should use Tik Tok content creators who advertise for free and at a cost of MHC sending a free sample to demonstrate. Of course MHC would need to sell the products on TIk Tok shop in order for content creators to access them and offer free promotions. TIk Tok viewers are probably between 16 to 40 but many of the tests are geared towards these ages and then we must remember that all these 18-40s have older family members they may buy a test for. Remember if you give a free test to 20 Tik Tok members who each have 20,000 plus followers for example that a potential sale to 400,000 off just 20 free samples! Times this by 50 free samples etc you see how quick it would be to get the brand out there for literally nothing. Then you have the benefits of being on TIK TOK shop. This would be great if they have a deal with Boots and use Tik Tok viewers to make people aware of the products and services etc. It would also help encourage direct sales to MHC and enhance the user rate of the digital data. MHC must be smart a use the 8m of cash wisely to gain traction to wellness tests which are the future of the business whilst Covid revenue is this available. Covid revenue is the key to growth without dilution and valuable for MHC. A recent surge in Covid cases will reflect in 2nd half results in my opinion as Boots will buy tests in advance based on the figures and projections to ensure they are stocked for winter 2024 and summer 2024. The market will only react to news flow from MHC which is expected imminently. Penny has a great opportunity to demonstrate the future of wellness testing combined with the importance of digital data which Poc Doc has demonstrated is the future |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
